As traditional compound utilization and cost continue to decline, high impact therapeutic categories are emerging to take their place. In 2018, compound kits and combo packs each represented less than 1% of total prescriptions and drug costs. However, their presence is of growing concern due to the lack of evidence supporting their use and packaging strategies that are associated with exorbitant pricing. These and other challenges call for careful oversight that includes identification, clinical review and intervention, and/or recommendation of therapeutic alternatives where appropriate to help control inappropriate utilization and spend. Watch the video blog to learn more.